Smith Asset Management Group LP decreased its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 31.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,370 shares of the biopharmaceutical company’s stock after selling 13,380 shares during the period. Smith Asset Management Group LP’s holdings in ChemoCentryx were worth $275,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of ChemoCentryx by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock worth $8,727,000 after buying an additional 47,475 shares in the last quarter. Thrivent Financial For Lutherans bought a new position in shares of ChemoCentryx during the first quarter worth approximately $852,000. P.A.W. Capital Corp raised its position in shares of ChemoCentryx by 33.3% in the first quarter. P.A.W. Capital Corp now owns 160,000 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 40,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of ChemoCentryx by 37.5% in the first quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock worth $936,000 after buying an additional 35,049 shares in the last quarter. Finally, Spark Investment Management LLC bought a new position in shares of ChemoCentryx during the first quarter worth approximately $1,050,000. 49.37% of the stock is currently owned by institutional investors and hedge funds.

Shares of ChemoCentryx, Inc. (CCXI) opened at 7.06 on Wednesday. The company’s market cap is $343.86 million. The company’s 50-day moving average price is $9.50 and its 200 day moving average price is $7.72. ChemoCentryx, Inc. has a 52 week low of $4.06 and a 52 week high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. The company had revenue of $8.94 million during the quarter. On average, equities analysts forecast that ChemoCentryx, Inc. will post ($0.90) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Smith Asset Management Group LP Has $275,000 Position in ChemoCentryx, Inc. (CCXI)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/smith-asset-management-group-lp-has-275000-position-in-chemocentryx-inc-ccxi/1493917.html.

A number of research analysts have recently commented on the company. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a report on Tuesday, August 8th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th. Finally, BidaskClub downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th.

In related news, insider Petrus Bekker sold 30,000 shares of ChemoCentryx stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $9.98, for a total value of $299,400.00. Following the sale, the insider now owns 65,963 shares of the company’s stock, valued at $658,310.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 223,649 shares of company stock worth $2,157,360. 26.80% of the stock is owned by company insiders.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.